Pre-Exposure Prophylaxis – Talk Bio

Actionable Insights Powered by AI

Gilead Expands HIV Drug Access, Yet Faces Criticism Over Exclusion of Middle-Income Countries

7 months ago talkbio0Tagged Exclusion Criteria, Generic licensing agreements, Gilead Sciences, HIV Drug Access, HIV prevention, Lenacapavir, middle-income countries, Pre-exposure, Pre-Exposure Prophylaxis

Gilead Sciences, HIV drug access, Lenacapavir, Generic licensing agreements, Middle-income countries exclusion, HIV prevention, Pre-exposure prophylaxis (PrEP)

FDA Grants Emergency Authorization for Invivyd’s Pemgarda Antibody Prophylactic Against COVID-19 in Immunocompromised Individuals

1 year ago talkbio0Tagged Adolescent (age group), Adults/, Approved, Condoms, Male, COVID19 (disease), Emergency Use Authorization, Half-Life Extended Monoclonal Antibody, immune compromise, Immunocompromised Host, Invivyd, Moderate (severity modifier), Pemgarda, pemivibart, Pre-Exposure Prophylaxis, Prophylactic treatment, Severe (severity modifier), United States Food and Drug Administration, VYD222

Invivyd, Pemgarda (pemivibart; formerly VYD222), Half-Life Extended Monoclonal Antibody, COVID-19 Prophylactic, Immunocompromised Patients, Emergency Use Authorization (EUA), FDA Approval, Moderate to Severe Immune Compromise, Pre-exposure Prophylaxis (Prevention) of COVID-19 in Adults/ Adolescents